MedPath

Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix

Not Applicable
Completed
Conditions
Preterm Birth
Interventions
Device: Silicon ring (Arabin Pessary)
Registration Number
NCT00706264
Lead Sponsor
Maternal-Infantil Vall d´Hebron Hospital
Brief Summary

Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length at 18-22 weeks scan.

Detailed Description

This trial includes pregnant women undergoing routine ultrasound examination at 18.0 to 22.6 weeks of gestation.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
385
Inclusion Criteria
  • Singleton pregnancy
  • Minimal age of 18 years
Exclusion Criteria
  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
  • SROM at the time of randomization
  • Cervical cerclage in situ
  • Active vaginal bleeding
  • Previous cone biopsy or cerclage
  • Major uterine structural anomalies
  • Placenta previa

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Silicon ring (Arabin Pessary)Placement of arabin pessary since 23 weeks until 37 weeks
Primary Outcome Measures
NameTimeMethod
Spontaneous Delivery Before 34 Completed WeeksBetween 24 and 34 weeks

Number of spontaneous preterm births before 34 weeks occurred in each group.

Secondary Outcome Measures
NameTimeMethod
Retinopathy of PrematurityBetween birth and 28 days of age

The number of neonatal retinopathy in the pessary group was compared to those in the no pessary group

Birthweight Less Than 1500 gTime of delivery

Number of newborns whose birthweight is less than 1500 grams

Birthweight Less Than 2500 gTime of delivery

Number of newborns whose birthweight is less than 2500 grams

Intrauterine Fetal DemisePregnancy

The number of fetal deaths in the pessary group was compared to those in the no pessary group

Neonatal DeathBetween birth and 28 days of age

The number of neonatal deaths in the pessary group was compared to those in the no pessary group

Intraventricular HaemorrhageBetween birth and 28 days of age

The number of neonatal intraventricular haemorrhage in the pessary group was compared to those in the no pessary group

Respiratory Distress SyndromeBetween birth and 28 days of age

The number of neonatal Respiratory distress syndrome in the pessary group was compared to those in the no pessary group

Treatment for SepsisBetween birth and 28 days of age

The number of neonatal cases of treatment needed for sepsis in the pessary group was compared to those in the no pessary group

Composite Adverse OutcomesBetween birth and 28 days of age

The number of neonatal cases with composite adverse outcomes in the pessary group was compared to those in the no pessary group

Spontaneous Delivery Before 28 Completed WeeksBetween 24 and 28 weeks

Number of preterm births before 28 weeks occurred in each group.

Any Delivery Before 34 Completed WeeksBetween 24 and 34 weeks

Number of all preterm births before 34 weeks occurred in each group.

Spontaneous Delivery Before 37 Completed WeeksBetween 24 and 37 weeks

Number of preterm births before 37 weeks occurred in each group.

Gestational Age at DeliveryAt time of birth

Number of weeks of gestation completed by time of delivery

Use of Tocolysisparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants required use of tocolytic medication

Use of Antenatal Steroidsparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants that received betamethasone to reduce morbidity of expected preterm delivery

Chorioamnionitisparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants that showed intrauterine infection diagnosed by maternal tachycardia, fever, uterine tenderness, purulent or abnormal cervical discharge, fetal tachycardia.

Vaginal Bleedingparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants who experienced bleeding from lower genital tract during antepartum period

Preterm Premature Rupture of Membranesparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants who experienced rupture of membranes as diagnosed by speculum exam showing pooling, ferning, positive nitrazine test, positive amnisure test.

Necrotising EnterocolitisBetween birth and 28 days of age

The number of neonatal necrotising enterocolitis in the pessary group was compared to those in the no pessary group

Cesarean DeliveryAt time of delivery

Number of participants that underwent cesarean delivery

Vaginal Dischargeparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants who experienced an increased vaginal discharge.

Pessary Repositioning Without Removalparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants who required pessary repositioning without removal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).

Pessary Withdrawalparticipants will be followed for the duration of pregnancy, up to nine months

Number of participants who experience pessary withdrawal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).

Trial Locations

Locations (6)

Hospital de Reus

🇪🇸

Reus, Tarragona, Spain

Hospital Materno-Infantil de Canarias

🇪🇸

Las Palmas de Gran Canaria, Gran Canaria, Spain

Hospital Vall d´Hebron

🇪🇸

Barcelona, Spain

Institut Universitary Dexeus

🇪🇸

Barcelona, Spain

Hospital Son Llàtzer

🇪🇸

Palma de Mallorca, Mallorca, Spain

Hospital de Fuenlabrada

🇪🇸

Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath